AV-203

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAV-203
Drug Alias NameCAN-017AV-203
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAveo
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd
Inactive CompaniesAveo Pharmaceuticals IncCANbridge (Shanghai) Life Sciences Ltd
Active IndicationsNeoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A